Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Select Medical Holdings (SEM) Depreciation & Amortization (CF) (2018 - 2025)

Select Medical Holdings (SEM) has disclosed Depreciation & Amortization (CF) for 8 consecutive years, with $36.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 20.85% to $36.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $70.6 million, a 65.35% decrease, with the full-year FY2025 number at $140.3 million, down 31.19% from a year prior.
  • Depreciation & Amortization (CF) was $36.2 million for Q4 2025 at Select Medical Holdings, up from $34.4 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $54.1 million in Q1 2024 to a low of $34.4 million in Q3 2025.
  • A 5-year average of $49.5 million and a median of $51.1 million in 2022 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): increased 8.01% in 2024, then plummeted 31.31% in 2025.
  • Select Medical Holdings' Depreciation & Amortization (CF) stood at $51.9 million in 2021, then rose by 0.58% to $52.2 million in 2022, then increased by 3.33% to $54.0 million in 2023, then dropped by 15.27% to $45.7 million in 2024, then decreased by 20.85% to $36.2 million in 2025.
  • Per Business Quant, the three most recent readings for SEM's Depreciation & Amortization (CF) are $36.2 million (Q4 2025), $34.4 million (Q3 2025), and $45.7 million (Q4 2024).